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iscussion
r Steven G. Swisher (Houston, Tex). This study reviews the
utcome of an uncommon subset of patients with esophageal
ancer: those patients with clinical T2N0 tumors as defined by
US. The authors make the observation that this group of patients
eem to be difficult to accurately stage by EUS, with only 7 of 53
atients (13%) actually having a pathologic T2N0 tumor. Some
5% of the EUS-staged patients were overstaged and 32% were
nderstaged, making proper treatment decisions difficult. The au-
hors then evaluate the outcome of these patients and suggest that
he optimal treatment for these patients is surgery first with post-
perative chemoradiation reserved for those patients who have
een understaged.
The article is to be commended for attempting to address an
ncommon group of patients for whom little data are available and
reatment decisions have not been defined. There are, however,
everal limitations to this study. It is retrospective and nonrandom-
zed, and because of this, it is subject to bias and selection. This
tudy was performed over a long period of time (20 years), with a
mall number of heterogeneous patients who were treated with
everal different treatment strategies. Because of these inherent
imitations, accurate treatment assessments and recommendations
re difficult to make even when performed with the aid of sophis-
icated statistical analyses.
I have several questions for the author. First, the accuracy of
US staging for T2 esophageal cancers is much lower than that
eported by recent groups who have used new EUS probes that
perate at a higher frequency (15-20 MHz), as opposed to the 7.5
Hz described here, in which the esophageal wall can be visual-
zed as a series of 7 or 9 layers. Would the use of these more
ccurate EUS miniprobes eliminate some of the staging inaccura-
ies reported in this study? e
The Journal of ThoracicDr Rice. No doubt the limitation of staging is ultrasound
echnology. As we look at the study period, we find that staging
ccuracy did not get any better over time, although we do use the
2-MHz probe to look within the wall and the 7.5-MHz probe to
ook distantly. The problem with adding more and more layers is
hat you have, of course, more and more interfaces to deal with.
o, although increasing technology may seem attractive, it could
dd more areas for error.
Dr Swisher. Second, I believe that you would agree it is
ifficult to come up with absolute conclusions about treatment
ecause this is a small, retrospective, nonrandomized study per-
ormed over a 20-year time period. How did the authors select the
patients treated with postoperative adjuvant treatment? Was the
ecision made because of age or performance status or because of
feeling by the surgeon that the tumor was at high risk for
ecurrence?
Dr Rice. There were 8 patients over approximately 18 years
ho received induction chemoradiation therapy, and, yes, they
robably were treated a little earlier in the series; now, we would
ever consider anyone with disease confined to the wall for induc-
ion therapy. Certainly in these 8 patients, there is a small amount
f induction toxicity and many tumor deaths, suggesting inaccu-
acy in staging. That is the best we could do. I agree it is a small
umber, but you must realize that it took us nearly 20 years to
ccumulate this experience; at our institution, where we perform
0 to 100 resections a year, that is only 2 patients per year.
Dr Swisher. Third, why do the authors think that their induc-
ion therapy experience was associated with such a poor outcome
n their study? At MD Anderson we reviewed 21 patients who
ere treated with preoperative chemoradiation and had EUS-
efined T2N0 tumors. They were treated with induction chemora-
iation since 1997, and their overall survival is 67% at 3 years
ather than the 13% 3-year survival reported by this study. Was the
ncreased toxicity reported by your group caused by the hyperfrac-
ionated radiation therapy and paclitaxel that were used?
Dr Rice. Only 1 of 7 deaths was due to toxicity; 6 were due to
ecurrent cancer.
Dr Mark J. Krasna (Baltimore, Md). Tom, as always, I
ompliment you and your group for helping to elucidate all of the
ne intricacies in the management of esophageal cancer, the stage-
pecific approach.
I will just reiterate what we just heard from Dr Swisher, that to
ake any kind of conclusion based on 7 of 53 patients would be
nappropriate when we walk out of this room, but we appreciate
he chance to discuss it. I do advise more than anything to caution
gainst what I now have heard several times as a tendency among
horacic surgeons to adopt a postoperative adjuvant therapy ap-
roach in dealing with patients with any stage of esophageal
ancer. To my knowledge, there are only 2 positive trials that
ould support that approach. One is a Chinese trial of adjuvant
adiation therapy alone for patients with esophageal cancer. The
nly other data that are available that are either prospective or
andomized are the results of the Gastric Cancer Study, which
ncluded patients who had total gastrectomies with D1, D2 resec-
ions, radical lymphadenectomies, and most of them splenecto-
ies. So, again, I would just caution, although I know yourxperience is excellent, to generalize this, that people not walk out
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G
TSf the room thinking that there is a proven role for adjuvant
adiation or chemoradiation for esophageal cancer.
Dr Rice. Can I turn that back to you? Where is the evidence for
he benefit of induction therapy? As surgeons, I would plead with
ou to do the operation first whenever possible. Then at least you
now the pathologic stage and can decide how to treat your patient.
f you are using induction chemoradiation therapy, two thirds of
our patients will not respond. That is as bad as giving them
ostoperative adjuvant therapy based on matched data or some
uestionable phase III data. But I stand, as you stand, with no
hase III study to help us. So, as a surgeon, take the cancer out
rst. You’ll be happy. At least you will know the pathologic stage.
Dr Krasna. Just to clarify, I do think that there are 3 phase III
rials out there, including the first one that was presented from the
roup in Michigan, as well as the Walsh study and recently the
ntergroup trial (CALGB 9781). Although all were small and some
ere questionable in terms of the long-term 5-year survival, espe-
ially for the Michigan trial, 2 of those 4 clearly showed a
ignificant advantage in 5-year survival, not just 1-, 2-, and 3-year
urvivals, with trimodality therapy over surgery alone.
Dr Rice. But two thirds of your patients are getting therapy
hey will not benefit from: toxic high-dose therapy.
Dr Krasna. In 2 of those trials, that’s correct. One of the trials
as a stage-specific approach.
Dr Steven DeMeester (Los Angeles, Calif). I’m glad to see that
our study is echoing some of the data we have presented as well,
hat patients, regardless of the size of the tumor (even in our
xperience, T3 tumors that are N0), have an excellent survival. I
hink that’s an important message, that the lymph node status is
uch more important than the size of the tumor.
I am a bit surprised how 10% of patients could be overstaged
hen they had only high-grade dysplasia. Did those patients have
biopsy that showed cancer, leading to the EUS that gave you the
isreading, or did they never have a biopsy of cancer? The
uestion is, how did that happen?
Dr Rice. That is only 3 patients.
Dr DeMeester. That’s 10% though.
Dr Rice. It’s 10%, and they did have a mass in a segment ofigh-grade dysplasia, but the biopsy was read as invasive cancer. g
24 The Journal of Thoracic and Cardiovascular Surgery ● FebrDr Antoon Lerut (Leuven, Belgium). You didn’t say anything
bout the lymph node ratio. How many lymph nodes were in-
olved and what was the ratio? Is the burden of lymph node
nvolvement comparable to what you find in the patients with T3?
ould the lymph node ratio be helpful in discriminating whether
ou would see that as an indication for adjuvant chemo/chemora-
iotherapy?
Dr Rice. Once we find N1 disease postoperatively, we try to
dminister postoperative adjuvant therapy. There is no doubt that
n our experience if a patient has 1 or 2 positive nodes, he or she
oes better than if 3 or more positive nodes are present, but that
urvival advantage is 10% versus 24% at 5 years. Still, if you want
o leave those patients with low lymph node burden unprotected,
hen that would be a way to direct your postoperative adjuvant
herapy.
Dr Joe B. Putnam Jr (Nashville, Tenn). I have no conflicts.
Tom, I appreciated the information that you presented here
oday and the lively discussion that has ensued.
As noted by the discussants, there are significant differences in
urvival that have been noted between single institutions. On the
asis of multiple single-institution studies, we have created para-
igms of cancer treatment, and there is a significant lack of
ulti-institutional trials in the prospective fashions. We have been
uccessful in some phase II studies, and phase III studies have not
een adequately subscribed to by our surgeons, medical oncolo-
ists, and radiation oncologists in a way that would allow rapid
ccrual, completion, and timely publication of the results. I would
ike your opinion as to the strategies that we can use to develop
hese multi-institutional trials to answer these significant problems,
hese significant questions that we have as surgeons and members
f multidisciplinary teams in the treatment of our patients with
sophageal cancer.
Dr Rice. For a phase III multi-institutional study, you obvi-
usly have to use high-volume centers. So, the first step is to get
hese centers to agree to participate. I believe that including low-
olume centers will eliminate any survival advantage through
ncreased operative or treatment mortality. The big boys have to
et together.
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